Conservative management of patients with early endometrial carcinoma: a systematic review.
OBJECTIVE
To know the characteristics of endometrial adenocarcinoma in young patients and to review the published experience in patients with endometrial adenocarcinoma that were conservatively managed with hormonal therapy to spare their fertility.


METHODS
We carried out a search in the Survey conducted by the Section of Oncologic Gynecology of SEGO (Spanish Society of Gynecologists) to identify the characteristics of young patients with endometrial adenocarcinoma. In addition we searched MEDLINE and other databases for English-language articles describing patients with endometrial adenocarcinoma who were treated with hormonal therapy. The search included articles published between January 1966 and January 2007.


RESULTS
Endometrial carcinoma in patients under 45 years old is an unusual condition that shows a more favourable pattern than in older patients. One hundred and thirty-three patients were found in the search. The average duration of hormonal therapy was approximately six months. The average response time was 12 weeks; 76% of patients treated with hormonal therapy had a complete response and the other 24% never responded to treatment. Of those who initially responded, 66% percent did not show recurrence of disease. The other 34% had a relapse. There have been 4 published deaths of conservatively managed patients.


CONCLUSIONS
A conservative approach in these patients can offer reasonable oncological security and the opportunity of fulfilling their maternal desires in selected cases. However, consideration should be taken regarding the potential adverse outcomes that have been recently published in the literature.
Chiva de Agustín
Luis
L
Departamento de Ginecología Oncológica, MD Anderson International, Madrid, Spain. Ichiva@mdanderson.es
Lapuente Sastre
Fernando
F
Corraliza Galán
Virginia
V
Granados Galainena
Luis
L
González Martín
Antonio
A
González Cortijo
Lucía
L
Carballo González
Natalia
N
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000473:pathology; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D016889:Endometrial Neoplasms / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D005298:Fertility; D006801:Humans; D011247:Pregnancy; D011256:Pregnancy Outcome
D018931:Antineoplastic Agents, Hormonal